title: Engineered T cells for anti-cancer therapy.
abstract: Recent advances enabling efficient delivery of transgenes to human T cells have created opportunities to address obstacles that previously hindered the application of T cell therapy to cancer. Modification of T cells with transgenes encoding TCRs or chimeric antigen receptors allows tumor specificity to be conferred on functionally distinct T cell subsets, and incorporation of costimulatory molecules or cytokines can enable engineered T cells to bypass local and systemic tolerance mechanisms. Clinical studies of genetically modified T cell therapy for cancer have shown notable success; however, these trials demonstrate that tumor therapy with engineered high avidity tumor-reactive T cells may be accompanied by significant on-target toxicity, necessitating careful selection of target antigens and development of strategies to eliminate transferred cells.
authors: Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
authors: Cameron J
authors: CJ
authors: Turtle
authors: Michael
authors: M
authors: Hudecek
authors: Michael C
authors: MC
authors: Jensen
authors: Stanley R
authors: SR
authors: Riddell
mesh_terms: D005818:Genetic Engineering / Q000379:methods* / Q000639:trends; D006680:HLA Antigens / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D009369:Neoplasms / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000378:metabolism; D016176:T-Lymphocyte Subsets / Q000276:immunology* / Q000378:metabolism / Q000637:transplantation*; D014161:Transduction, Genetic
chemical_list: D006680:HLA Antigens; D011948:Receptors, Antigen, T-Cell